Northwest Biotherapeutics reported $-10.9M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Agenus USD 15.05M 656K Mar/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Celldex Therapeutics USD -80.62M 3.81M Jun/2026
Eisai JPY 24.73B 35.04B Jun/2026
Merck USD 840M 2.72B Jun/2026
Northwest Biotherapeutics USD -10.9M 3.42M Mar/2026
Pfizer USD 667M 4.32B Jun/2026
Plus Therapeutics USD -7.12M 1.38M Mar/2026
Roche Holding CHF 11.46B 1.91B Jun/2026